written by reader Guaranteed Weight Loss without Surgery, Drugs or Dieting! (Really!)

by DrKSSMDPhD | May 3, 2014 12:56 pm

But Is This Biotech a Good Investment?

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://www.stockgumshoe.com/2014/05/microblog-guaranteed-weight-loss-without-surgery-drugs-or-dieting-really/


664 responses to “written by reader Guaranteed Weight Loss without Surgery, Drugs or Dieting! (Really!)”

  1. 1paglee says:

    At lest the Nasdaq biotech index had turned decidedly bullish. Here’s a link:
    http://stockcharts.com/def/servlet/SC.pnf?c=%24nbi,P

  2. hblytt says:

    Wonderful article, as always, Dr KSS. Wonderful discussion. I’d like to bring up a theory about obesity the was propounded by CS Forester in one of his WW 2 novels. An English girl travels to a tropical posting. She finds the Englishwomen there are slender. She feels pudgy. It is explained to her that living in the tropics causes slenderness, because you feel like eating less. This makes sound physiological sense: (Body mass)/(skin area) is lower in warm climates. So perhaps the fault is not in my eating habits, but in the air conditioning.

  3. SoGiAm says:

    CNDO-Coronado Biosciences Says Offering Generated Total Gross Proceeds of $42M>CNDO (Dow Jones) Is this equity worth revisiting? No Position Best-Ben

  4. SoGiAm says:

    CNDO-Another one to feed our dragons Hi Pockets ha- From TLOGlolytes post 157-
    To Ben/sogiam: I think you were asking on another thread about Coronado Biosciences $CNDO. This company has a strongly positive KSS ratio with short interest 12 percent and institutional interest at 16 percent. I view it as extraordinarily lost, and its plans to use gut parasites to treat psoriasis and autism are not grounded in reality. It’s almost as if Patch Adams is running Coronado. Its NK cell idea is nice but likely to fail in its present form, and other up and coming companies are doing much better NK cell work. It is overvalued, spending money in the most foolhardy way imaginable, and is just not with the program as regards modern biotech. I strongly encourage avoiding here. It is as if, following their IBD trial failures earlier this year, they have gone slightly toys-in-attic. I won’t totally rule out their parasite having an effect in UC, which is quite different biologically from Crohn’s (where it failed), but overall I doubt it will work, and am sure that almost no patients would ever agree to be so treated if it were approved as a product.
    ONCS–as well…from post 141 TLOGlogytes-ONCS’s method is quite similar to perennially underperforming and roundly teased stock Ziopharm. Both want to play with IL-12, which upregulates immune activity against cancer cells. Bear in mind, however, that cancer is a systemic disease in most cases, and that they want to electroporate melanoma lesions seems doomed to fail. ONCS has a DNA piece encoding IL-12, and they want to bung this into melanoma as a way of summoning immune attack. On a science/clinical/instinct basis, I given this approach at most a 10 per cent chance of helping patients, and would note it may well hurt them, both the physical pain of electroporation, but the fact that this approach could free up cells to metastasize.
    Regardless of the hooey from ONCs and INO, electroporation is a very very inefficient and low-efficacy method for getting a gene expressed in a target cell. I would not touch $ONCS.
    Thanks Dungeonmeister and Dr. KSS. Best to ALL-Ben

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.